News
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens Entasis Therapeutics Holdings Inc. Thu, Jul 1, 2021, 8:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback